tiprankstipranks
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

NXTC Stock Latest News

NextCure Updates Presentation on LNCB74 Clinical Trial
Company AnnouncementsNextCure Updates Presentation on LNCB74 Clinical Trial
20d ago
8K
NXTC
Optimistic Buy Rating for NextCure Driven by Promising Developments in LNCB74 for Endometrial Cancer
PremiumRatings
Optimistic Buy Rating for NextCure Driven by Promising Developments in LNCB74 for Endometrial Cancer
1M ago
NXTC
H.C. Wainwright says competitor data builds optimism for NextCure’s LNCB74
PremiumThe Fly
H.C. Wainwright says competitor data builds optimism for NextCure’s LNCB74
1M ago
AZN
PFE
Nextcure Faces Delisting Risk Amid Nasdaq Compliance Struggles
PremiumCompany Announcements
Nextcure Faces Delisting Risk Amid Nasdaq Compliance Struggles
2M ago
NXTC
NextCure Reports 2024 Financials and Strategic Progress
PremiumCompany Announcements
NextCure Reports 2024 Financials and Strategic Progress
2M ago
NXTC
NextCure’s Promising Trajectory: Buy Rating Backed by Clinical Progress and Competitive Edge
PremiumRatingsNextCure’s Promising Trajectory: Buy Rating Backed by Clinical Progress and Competitive Edge
2M ago
NXTC
NextCure announces first patient dosed in Phase 1 study of LNCB74
Premium
The Fly
NextCure announces first patient dosed in Phase 1 study of LNCB74
4M ago
NXTC
NextCure announces acceptance of IND application for LNCB74
Premium
The Fly
NextCure announces acceptance of IND application for LNCB74
5M ago
NXTC
NextCure Advances with New Cancer Drug Application
PremiumCompany Announcements
NextCure Advances with New Cancer Drug Application
5M ago
8K
NXTC
NextCure announces preclinical data on NC605
PremiumThe Fly
NextCure announces preclinical data on NC605
5M ago
NXTC
NextCure Reports Improved Financial Performance and Strategic Focus
PremiumCompany Announcements
NextCure Reports Improved Financial Performance and Strategic Focus
6M ago
NXTC
NextCure to Discuss Innovative Cancer Therapies
PremiumCompany Announcements
NextCure to Discuss Innovative Cancer Therapies
6M ago
8K
NXTC
NextCure reports Q3 EPS (41c), consensus (34c)
PremiumThe FlyNextCure reports Q3 EPS (41c), consensus (34c)
6M ago
NXTC
NextCure reports data from LNCB74, NC410 studies
Premium
The Fly
NextCure reports data from LNCB74, NC410 studies
6M ago
NXTC
NXTC Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
NXTC Upcoming Earnings Report: What to Expect?
6M ago
NXTC
NextCure announces data from Phase 1b trial evaluating NC410
PremiumThe Fly
NextCure announces data from Phase 1b trial evaluating NC410
8M ago
NXTC
NextCure reports Q2 EPS (55c), consensus (38c)
PremiumThe Fly
NextCure reports Q2 EPS (55c), consensus (38c)
9M ago
NXTC
NextCure presents Phase 1b data on NC410 and pembrolizumab combo at ASCO
PremiumThe Fly
NextCure presents Phase 1b data on NC410 and pembrolizumab combo at ASCO
11M ago
NXTC
NextCure treatment of osteogenesis imperfecta granted orphan designation
PremiumThe Fly
NextCure treatment of osteogenesis imperfecta granted orphan designation
11M ago
NXTC
NextCure reports Q1 EPS (61c), consensus (46c)
PremiumThe FlyNextCure reports Q1 EPS (61c), consensus (46c)
12M ago
NXTC
NextCure and LCB present data on B7-H4 antibody drug conjugate at AACR
Premium
The Fly
NextCure and LCB present data on B7-H4 antibody drug conjugate at AACR
1y ago
NXTC
NextCure appoints Rakesh Dixit to Scientific Advisory Board
Premium
The Fly
NextCure appoints Rakesh Dixit to Scientific Advisory Board
1y ago
NXTC

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >